KOLFILD Tomas Dzh. (US),КОЛФИЛД Томас Дж. (US),KLEMENS Dzhennifer (US),КЛЕМЕНС Дженнифер (US),FREhNSIS Robert S. (US),ФРЭНСИС Роберт С. (US),FRID Brajan S. (US),ФРИД Брайан С. (US),DZhON Stehnli (US),KOLFILD TOMAS DZH.,КОЛФИЛД Томас Дж.,KLEMENS DZHENNIFER,КЛЕМЕНС Дженнифер,FREHNSIS ROBERT S.,ФРЭНСИС Роберт С.,FRID BRAJAN S.,ФРИД Брайан С.,DZHON STEHNLI,ДЖОН Стэнли,LE TIEU-BINKH,ЛЕ Тиеу-Бинх,PEDGRI
申请号：
RU2009149465/04
公开号：
RU0002477279C2
申请日:
2008.06.04
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to compounds of formula 1a:, wherein: A means CH=CH orS； R23 means hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)-alkyloxy or (C1-C4)-alkyl-S-； R24 means hydrogen or halogen when A means CH=CH or hydrogen, halogen, (C1-C4)-alkyl when A means S； X means N(H)C=O, N(H)S(O)2, C=ON(H) or S(O)2N(H)； Y means C(R12)=C(R13), N=C(R14) or C(R15)=N, or condensed optionally substituted 5-7-member carbocyclyl； R12 means hydrogen, halogen, (C1-C10)-alkyl, (C2-C10)-alkenyl, (C3-C6)-cycloalkyloxy, (C3-C10)-cycloalkenyloxy, (C3-C6)-cycloalkyl, (C3-C10)-cycloalkenyl, (C3-C6)-cycloalkyl[(C1-C4)-alkyl or (C2-C4)-alkenyl], (C3-C6)-cycloalkyl (C1-C4)-alkyloxy, (C1-C10)-alkyloxy, (C3-C10)-alkenyloxy, (C1-C10)-alkyl-S-, cyano, (C1-C10)-alkylcarbonyl- or phenyl； R13 means hydrogen, halogen or (C1)-alkyl； R14 means hydrogen or (C1-C3)-alkyl-S(O)m； R15 means hydrogen, halogen, (C1-C10)-alkyl, amino, [(C1-C10)-alkyl or (C2-C10)-alkenyl] amino, [(C1-C10)-alkyl or (C2-C10)-alkenyl]((C1-C10)-alkyl)amino or nitro； R21 means hydrogen； R22 means hydrogen, halogen, (C1)-alkyl, while Y means C(R12)=C(R13), N=C(R14) or C(R15)=N； R51 means COOH or CONH(R53)； R53 means R55-SO2- or tetrazolyl； R55 means (C1-C4)-alkly； and m is equal to 0； wherein all specified phenyl groups may be independently substituted by one or more halogen atoms； wherein all specified alkyl groups may be independently substituted by one or more fluorine atoms； or its stereoisomer form, a mixture of stereoisomer forms in any ratio or its physiologically acceptable salt, provided the following compounds are excluded: 2-benzoylamino-2,3-dihydro-2-indencarboxylic acid； 2-(naphthalin-2-ylsulphonylamino)indane-2-carboxylic acid. Also, the invention refers to a pharmaceutical composition possessing CXCR5 receptor inhibitory activity on the basis of the compounds described above, as well as a method of treating a patient, involving introducing said compounds into the patient.EFFEC
